Iloperidone Dosage

Medically reviewed by Drugs.com. Last updated on Jan 26, 2024.

Applies to the following strengths: 1 mg; 2 mg; 4 mg; 6 mg; 8 mg; 10 mg; 12 mg; 1 mg-2 mg-4 mg-6 mg

Usual Adult Dose for:

Schizophrenia

Additional dosage information:

Renal Dose Adjustments
Liver Dose Adjustments
Dose Adjustments
Precautions
Dialysis
Other Comments

Usual Adult Dose for Schizophrenia

Initial dose: 1 mg orally twice a day
Maintenance dose: 6 to 12 mg twice a day
Maximum dose: 24 mg/day

Comments:

This drug must be titrated slowly to avoid orthostatic hypotension.
Control of symptoms may be delayed during the first 1 to 2 weeks of treatment because of the need to titrate slowly.
Treatment should be increased in increments of not more than 2 mg twice daily as tolerated.
Healthcare providers should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.

Use: Treatment of schizophrenia

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

Mild liver dysfunction: No adjustment recommended.
Moderate liver dysfunction: Dosage adjustment(s) may be required; however, no specific guidelines have been suggested. Caution recommended.
Severe liver dysfunction: Not recommended.

Dose Adjustments

CYP450 2D6 poor metabolizers:

Reduce the dose by one-half.

Concomitant use with strong CYP450 2D6 and/or 3A4 inhibitors:

Reduce the dose by one-half when administered with strong CYP450 2D6 inhibitors (e.g., fluoxetine, paroxetine) or strong CYP450 3A4 inhibitors (e.g., ketoconazole, clarithromycin).
When the inhibitor is stopped, the dose may be increased to where it was before.

Precautions

US BOXED WARNINGS:
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
This drug is not approved for use in patients with dementia-related psychosis.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration Advice:

This drug may be taken with or without food.

Storage requirements:

Protect from light and moisture.

General:

Prior to starting treatment, healthcare providers should take into account need for dose titration and therefore delay in symptom control, and QT interval prolongation risk.
For patients reinitiating treatment after an off interval of more than 3 days, the initial titration schedule should be followed.
Controlled clinical trials have shown a delay in time to relapse in patients with schizophrenia.
No specific recommendations are available regarding switching from other antipsychotics or for the use of concomitant antipsychotics.

Monitoring:

Cardiovascular: Orthostatic vital signs in at-risk patients
Hematologic: CBC frequently during the first few months in patients with preexisting low WBC and/or a prior history of drug-induced leukopenia or neutropenia.
Metabolic: Increases in blood sugar, weight, and lipids

Patient Advice:

Inform patients that this drug may cause dizziness upon arising; tell patients that it is best to get up slowly form a seated or lying position.
This drug may impair judgment, thinking, or motor skills; patients should be told to avoid driving or operating machinery until adverse effects are determined.
Advise patients to speak to their health care provider if they are pregnant, intend to become pregnant, or are breastfeeding.
Advise patients that this drug may cause metabolic changes (e.g., increases in blood sugar, body weight and lipids).
Patients should avoid overheating and dehydration.